Canada’s life sciences sector is poised to turn research into health solutions for addressing health threats. There is a central challenge: existing practices, policies, and processes slow patient access to new technologies.
With support from Genome BC’s Immunoengineering Strategic Initiatives (GISI) and Health Research BC, a new initiative aims to change that.
The Platform for Regulatory Science, Innovation, and Equitable Health Systems (PRISm) will position British Columbia—and Canada—as a global leader in regulatory science. By engaging communities and tapping into BC’s robust data ecosystem, PRISm will make sure that new health discoveries reach patients sooner.
Led by Dr. Dean Regier, Director, Academy of Translational Medicine, University of British Columbia and Senior Scientist at BC Cancer, PRISm brings together scientists from different fields to collaborate in an innovative way, driving systems change. This research will:
1. Simplify data capture and access, finding new ways to share crucial information across health systems.
2. Fast track product development, producing clinical, economic, and equity evidence that makes downstream healthcare decisions easier.
3. Quickly transition innovations to the market and to health systems, focusing on equity, safety, value, and sustainability.
4. Mentor students and new researchers, building the next generation of experts.
Community engagement is central to PRISm. Together, we will ensure that the evidence we produce responds to the needs of diverse populations. Collaborations with governments and industry will make our research findings policy-relevant and immediately actionable.
Through inclusive research, training, and decision-making, PRISm will help build a learning health system for Canada—one that is equitable, evidence-driven, and resilient in the face of health threats.